FengHe Fund Management Pte. Ltd. Makes New $17.71 Million Investment in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• FengHe Fund Management established a new position in Arrowhead (NASDAQ:ARWR), purchasing 266,700 shares valued at about $17.71 million in Q4, making it roughly 1.0% of the fund's portfolio and its 25th-largest holding.
• Analyst sentiment has turned more positive—several firms raised price targets (e.g., Morgan Stanley to $100, Piper Sandler to $110), and Arrowhead's consensus rating is a Moderate Buy with an average target of $83.78.
• Arrowhead reported Q4 revenue of $264.0M (above estimates) but missed on EPS ($0.22 vs. $0.60), and insiders sold about 33,095 shares (~$2.33M) under pre-arranged Rule 10b5-1 plans.

FengHe Fund Management Pte. Ltd. purchased a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 266,700 shares of the biotechnology company's stock, valued at approximately $17,706,000. Arrowhead Pharmaceuticals comprises about 1.0% of FengHe Fund Management Pte. Ltd.'s investment portfolio, making the stock its 25th biggest position. FengHe Fund Management Pte. Ltd. owned about 0.19% of Arrowhead Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. CWM LLC increased its position in shares of Arrowhead Pharmaceuticals by 1.4% during the 4th quarter. CWM LLC now owns 12,347 shares of the biotechnology company's stock worth $820,000 after purchasing an additional 168 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of Arrowhead Pharmaceuticals by 3.1% during the 3rd quarter. PNC Financial Services Group Inc. now owns 10,924 shares of the biotechnology company's stock worth $377,000 after purchasing an additional 326 shares during the last quarter. WPG Advisers LLC increased its position in shares of Arrowhead Pharmaceuticals by 384.8% during the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 431 shares during the last quarter. First Horizon Corp bought a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $32,000. Finally, State of Wyoming raised its stake in Arrowhead Pharmaceuticals by 5.6% in the third quarter. State of Wyoming now owns 9,519 shares of the biotechnology company's stock valued at $328,000 after buying an additional 504 shares during the period. Institutional investors and hedge funds own 62.61% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on ARWR shares. Chardan Capital raised their price objective on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a "buy" rating in a research report on Wednesday, January 7th. Morgan Stanley raised Arrowhead Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $78.00 to $100.00 in a report on Tuesday, April 21st. The Goldman Sachs Group boosted their target price on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a "neutral" rating in a report on Wednesday, January 7th. Piper Sandler reissued an "overweight" rating and set a $110.00 target price (up from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th. Finally, HC Wainwright reissued a "buy" rating and set a $100.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $83.78.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ ARWR opened at $73.60 on Tuesday. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.38 and a quick ratio of 3.38. The stock's fifty day moving average price is $63.02 and its two-hundred day moving average price is $58.77. Arrowhead Pharmaceuticals, Inc. has a one year low of $12.44 and a one year high of $76.76. The firm has a market cap of $10.31 billion, a price-to-earnings ratio of 48.10 and a beta of 1.26.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 EPS for the quarter, missing analysts' consensus estimates of $0.60 by ($0.38). The firm had revenue of $264.03 million during the quarter, compared to analyst estimates of $225.66 million. Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The business's quarterly revenue was up 10461.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.39) earnings per share. On average, equities analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3.37 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Daniel Joseph Apel sold 13,095 shares of the company's stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total transaction of $934,328.25. Following the completion of the sale, the chief financial officer directly owned 162,905 shares in the company, valued at approximately $11,623,271.75. This represents a 7.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James C. Hamilton sold 10,000 shares of the company's stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total value of $750,000.00. Following the sale, the insider owned 226,958 shares of the company's stock, valued at approximately $17,021,850. The trade was a 4.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 33,095 shares of company stock valued at $2,326,228. Corporate insiders own 3.60% of the company's stock.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.